BOCA RATON, Fla., Oct. 6, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that management will participate in two upcoming conferences:
- Joe Sardano, CEO and Steve Cohen, EVP will participate in the 2016 Fall Clinical Dermatology Conference to be held at the Encore at the Wynn in Las Vegas, NV on Thursday, October 20, 2016 – Sunday, October 23, 2016. The 2016 Fall Clinical Dermatology Conference is a four day event that gathers practicing dermatologists from across the nation to receive a comprehensive update on the diagnosis and treatment on a variety of conditions that face dermatologists on a daily basis.
- Arthur Levine, CFO and Kal Fishman, CTO will present at the Dawson James 2016 Small Cap Growth Stock Conference, to be held at the Wyndham Grand Hotel in Jupiter, FL, at 11:45am ET on Thursday, October 20, 2016.
“Attending the Fall Clinical Dermatology Conference provides Sensus Healthcare with a unique opportunity to share our innovative technology with a large group of our targeted customers, practicing dermatologists. Similarly, the Dawson James event allows us to present the Sensus investor story to a large audience comprised of micro-cap-oriented institutional investors,” said Joe Sardano, Chief Executive Officer of Sensus Healthcare.
Investors attending the conferences who wish to meet with management for a one-on-one meeting should notify their appropriate contact.
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://sensus.ericchesbrough.com.
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-important-dermatological-and-institutional-investor-conferences-from-october-20th-to-october-23rd-300340339.html
SOURCE Sensus Healthcare